Nothing Special   »   [go: up one dir, main page]

CY1107433T1 - Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων - Google Patents

Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων

Info

Publication number
CY1107433T1
CY1107433T1 CY20071100359T CY071100359T CY1107433T1 CY 1107433 T1 CY1107433 T1 CY 1107433T1 CY 20071100359 T CY20071100359 T CY 20071100359T CY 071100359 T CY071100359 T CY 071100359T CY 1107433 T1 CY1107433 T1 CY 1107433T1
Authority
CY
Cyprus
Prior art keywords
treatment
pipepidin
benzoyloyl
inflammations
pyrazol
Prior art date
Application number
CY20071100359T
Other languages
English (en)
Inventor
David R Borcherding
Alexandre Gross
Patrick Wai-Kwok Shum
Nicole Willard
Brian S Freed
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of CY1107433T1 publication Critical patent/CY1107433T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου (I) όπου ( ) είναι προαιρετική γέφυρα αιθυλενίου· R1 είναι αλκύλιο, κυκλοαλκύλιο, αρύλιο ή αρύλιο υποκατεστημένο με έναν ή περισσότερους υποκατάστατες επιλεγόμενους από αλκύλιο, αλκοξυ ομάδα και αμινο ομάδα, ή R1 είναι πυριδύλιο ή πυριδύλιο υποκατεστημένο με έναν ή περισσότερους υποκατάστατες επιλεγόμενους από αλκύλιο, αλκοξυ ομάδα και αμινο ομάδα· R2 είναι προαιρετικά υποκατεστημένο αλκύλιο, αλκοξυαλκύλιο, προαιρετικά υποκατεστημένο κυκλοαλκυλαλκύλιο, αρυλαλκύλιο, ή R2 είναι αρυλαλκύλιο υποκατεστημένο με έναν ή περισσότερους υποκαταστάτες επιλεγόμενους από αλκύλιο, αλκοξυ ομάδα· Χ είναι -C(O)-, -C(Ο)-CH2-, -S(Ο)2-, ή NH-C(O)-· και Α είναι προαιρετικά υποκατεστημένο αλκύλιο ή άλλοι υποκατάστατες όπως ορίζονται στην αξίωση 1. Φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις, η παρασκευή αυτών, και η φαρμακευτική χρήση αυτών στην αντιμετώπιση παθολογικών καταστάσεων που μπορούν να ελεγχθούν μέσω της αναστολής της p38-κινάσης και/ή του παράγοντα νέκρωσης όγκων (TNF), όπως άσθματος ή φλεγμονής αρθρώσεων.
CY20071100359T 2003-05-06 2007-03-15 Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων CY1107433T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46828503P 2003-05-06 2003-05-06
EP04751319A EP1622610B1 (en) 2003-05-06 2004-05-05 1-(2h-pyrazol-3-yl)-3-{4-[1-(benzoyl)-piperidin-4-ylmethyl]-phenyl}-urea derivatives and related compounds as inhibitors of p38 kinase and/or tnf inhibitors for the treatment of inflammations

Publications (1)

Publication Number Publication Date
CY1107433T1 true CY1107433T1 (el) 2012-12-19

Family

ID=28792177

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100359T CY1107433T1 (el) 2003-05-06 2007-03-15 Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων

Country Status (26)

Country Link
US (1) US7541368B2 (el)
EP (1) EP1622610B1 (el)
JP (1) JP4714150B2 (el)
AT (1) ATE348610T1 (el)
AU (2) AU2004238241A1 (el)
BR (1) BRPI0409991A (el)
CA (1) CA2524043C (el)
CL (1) CL2004000965A1 (el)
CY (1) CY1107433T1 (el)
DE (1) DE602004003806T2 (el)
DK (1) DK1622610T3 (el)
ES (1) ES2277271T3 (el)
GB (1) GB0320244D0 (el)
HN (1) HN2004000150A (el)
HR (1) HRP20070020T3 (el)
JO (1) JO2473B1 (el)
MX (1) MXPA05011400A (el)
MY (1) MY140830A (el)
PA (1) PA8601901A1 (el)
PE (1) PE20050523A1 (el)
PL (1) PL1622610T3 (el)
PT (1) PT1622610E (el)
SI (1) SI1622610T1 (el)
TW (1) TWI335223B (el)
UY (1) UY28310A1 (el)
WO (1) WO2004100946A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1761520B1 (en) 2004-06-23 2008-07-09 Eli Lilly And Company Kinase inhibitors
EP1778686B9 (en) 2004-08-12 2009-07-08 Pfizer Limited Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2007089646A1 (en) 2006-01-31 2007-08-09 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
US20090270350A1 (en) * 2006-02-10 2009-10-29 Pfizer Inc. Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
MX2009002019A (es) 2006-08-24 2009-03-09 Novartis Ag Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros.
CN101516877B (zh) 2006-09-22 2013-09-11 诺瓦提斯公司 杂环有机化合物
US8258160B2 (en) 2006-12-20 2012-09-04 Novartis Ag SCD1 inhibitors triazole and tetrazole compounds
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
EA020641B1 (ru) 2008-10-02 2014-12-30 Респайверт Лимитед Производные n-(1-фенил-3-алкилпиразол-5-ил)-n'-арилмочевины
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
MX2011006219A (es) * 2008-12-11 2011-06-28 Respivert Ltd Inhibidores de la proteina cinasa activada por el mitogeno p38.
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2236505A1 (de) 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
WO2011021645A1 (ja) * 2009-08-19 2011-02-24 大日本住友製薬株式会社 2環性ウレア誘導体、またはその薬学的に許容される塩
EP2503887B1 (en) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
JP5787977B2 (ja) * 2010-04-08 2015-09-30 レスピバート・リミテツド P38mapキナーゼ阻害剤
KR101332830B1 (ko) 2012-07-05 2013-11-27 한국화학연구원 페닐우레아 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 항암감작제
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
AU2017228398A1 (en) 2016-03-03 2018-10-18 Cornell University Small molecule IRE1-alpha inhibitors
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3142097A1 (en) 2018-05-30 2019-12-05 Washington University Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
CA3120514A1 (en) * 2018-11-20 2020-05-28 Sironax Ltd Cyclic ureas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1043995T1 (de) * 1997-12-22 2001-06-07 Bayer Corp., Pittsburgh INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents

Also Published As

Publication number Publication date
HRP20070020T3 (en) 2007-04-30
ATE348610T1 (de) 2007-01-15
HN2004000150A (es) 2008-03-03
CA2524043A1 (en) 2004-11-25
BRPI0409991A (pt) 2006-05-09
MY140830A (en) 2010-01-29
EP1622610A1 (en) 2006-02-08
WO2004100946A1 (en) 2004-11-25
TW200509912A (en) 2005-03-16
JO2473B1 (en) 2009-01-20
CA2524043C (en) 2009-12-29
JP4714150B2 (ja) 2011-06-29
DE602004003806T2 (de) 2007-11-22
AU2010236021A1 (en) 2010-11-18
JP2007502324A (ja) 2007-02-08
PE20050523A1 (es) 2005-07-07
DE602004003806D1 (de) 2007-02-01
US20060063796A1 (en) 2006-03-23
UY28310A1 (es) 2004-11-30
SI1622610T1 (sl) 2007-04-30
MXPA05011400A (es) 2005-12-12
DK1622610T3 (da) 2007-04-23
ES2277271T3 (es) 2007-07-01
TWI335223B (en) 2011-01-01
CL2004000965A1 (es) 2005-04-22
PA8601901A1 (es) 2004-11-26
EP1622610B1 (en) 2006-12-20
PL1622610T3 (pl) 2007-05-31
AU2004238241A1 (en) 2004-11-25
GB0320244D0 (en) 2003-10-01
US7541368B2 (en) 2009-06-02
PT1622610E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
CY1107433T1 (el) Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
CY1114037T1 (el) 2-(μορφολιν-4-υλ) πυριμιδινες ως αναστολεις της κινασης της φωσφατιδυλο-ινοσιτολης (ρι) 3 και η χρηση τους στη θεραπεια του καρκινου
EA200700902A1 (ru) 3-ариламинопиридиновые производные
SE0402762D0 (sv) Indazole sulphonamide derivatives
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
SE0202463D0 (sv) Novel compounds
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
MX2007009372A (es) Nuevos compuestos ii derivados de 2-piridina como inhibidores de elastasa neutrofila.
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
DK1458713T3 (da) Indolinonderivater anvendelige som proteinkinaseinhibitorer
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
ATE279410T1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
EA200501233A1 (ru) 4-аминопиримидин-5-он
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0104326D0 (sv) Therapeutic heterocycles